Sarcoma
Welcome,         Profile    Billing    Logout  
 504 Companies   302 Products   302 Products   167 Mechanisms of Action   1357 Trials   122306 News 


12345678910111213...15251526»
  • ||||||||||  Journal:  Circ_0049271 targets the miR-1197/PTRF axis to attenuate the malignancy of osteosarcoma. (Pubmed Central) -  Jun 29, 2024   
    Upregulation of miR-1197 reversed the antitumor effects of circ_0049271 on OS progression in vitro; however, PTRF overexpression attenuated the cancer-promoting effects of miR-1197 on OS in vitro. Our findings revealed that circ_0049271 targeted the miR-1197/PTRF axis to attenuate the malignancy of OS, suggesting a potential target for its clinical treatment.
  • ||||||||||  imatinib / Generic mfg.
    Journal, Stroma:  RAF1 facilitates KIT signaling and serves as a potential treatment target for gastrointestinal stromal tumor. (Pubmed Central) -  Jun 28, 2024   
    Inhibition of RAF1 in vivo suppressed GIST growth in a transgenic mouse model carrying germline KIT/V558A mutation, showing a similar treatment efficiency as imatinib, the first-line targeted therapeutic drug of GIST, while the combination use of imatinib and RAF1 inhibitor further suppressed tumor growth...However, the activation of secondary KIT mutation is less dependent on RAF1 compared with that of primary KIT mutations. Taken together, our results revealed that RAF1 facilitates KIT signaling and KIT mutation-mediated tumorigenesis of GIST, providing a rationale for further investigation into the use of RAF1 inhibitors alone or in combination with KIT inhibitor in the treatment of GIST, particularly in cases resistant to KIT inhibitors.
  • ||||||||||  Journal, CAR T-Cell Therapy, IO biomarker:  CAR-T cell expansion platforms yield distinct T cell differentiation states. (Pubmed Central) -  Jun 28, 2024   
    Intriguingly, our results suggest that oxygenation is responsible, at least in part, for observed differences in T cell phenotype among bioreactors and suggest hypoxic culture as a potential strategy prevent T cell differentiation during expansion. Ultimately, our study demonstrates that selection of bioreactor system may have profound effects not only on the capacity for expansion, but also on the differentiation state of the resulting CAR-T cells.
  • ||||||||||  Review, Journal:  Epidemiology of Cancer in Kidney Transplant Recipients. (Pubmed Central) -  Jun 28, 2024   
    Clinical care and future research should focus on prevention and on improving outcomes for important immunosuppression-related malignancies, and treatment options for other cancers occurring in the transplant setting. Semin Nephrol 36:x-xx
  • ||||||||||  Review, Journal:  Premalignant Lesions in the Kidney Transplant Candidate. (Pubmed Central) -  Jun 28, 2024   
    This review covers the less common premalignant lesions (intraductal papillary mucinous neoplasm, gastrointestinal stromal tumor, thymoma, and pancreatic neuroendocrine tumor) that can be found in the transplant candidate population. High-level evidence for the management of these rarer premalignant lesions in the transplant population is lacking, and this review extrapolates evidence from the general population and should not be a substitute for a multidisciplinary discussion with medical and surgical oncologists.
  • ||||||||||  Journal:  Inflammasome activation in patients with Kaposi sarcoma herpesvirus (KSHV)-associated disorders. (Pubmed Central) -  Jun 28, 2024   
    Finally, both supervised and unsupervised analyses with inflammasome measurements and other inflammatory biomarkers demonstrate a unique inflammatory profile in patients with PEL, MCD, and KICS as compared to KS. Our data indicate that detrimental inflammation in patients with KAD is at least partially driven by KSHV-induced inflammasome activation in monocytes, thus offering novel approaches to diagnose and treat these complex disorders.
  • ||||||||||  Journal:  Roadmap for the next generation of Children's Oncology Group rhabdomyosarcoma trials. (Pubmed Central) -  Jun 28, 2024   
    Given these challenges, systematic planning of future clinical trials in RMS is paramount to address pertinent questions regarding the therapeutic efficacy of drugs, biomarkers of response, treatment-related toxicity, and patient quality of life. Herein, the authors outline the proposed strategic approach of the Children's Oncology Group Soft Tissue Sarcoma Committee to the next generation of RMS clinical trials, focusing on five themes: improved novel agent identification and preclinical to clinical translation, more efficient trial development and implementation, expanded opportunities for knowledge generation during trials, therapeutic toxicity reduction and quality of life, and patient engagement.
  • ||||||||||  Journal:  Modeling 3D Tumor Invasiveness to Modulate Macrophage Phenotype in a Human-based Hydrogel Platform. (Pubmed Central) -  Jun 28, 2024   
    This pro-tumoral microenvironment was also found to enhance tumor invasiveness ability and proliferation. Besides providing a robust in vitro immunomodulatory tumor model that faithfully recreates the tumor-macrophage interplay, this human-based platform has the potential to provide fundamental insights into immunosuppressive signaling and predict immune-targeted response.
  • ||||||||||  pegylated liposomal doxorubicin / Generic mfg., alendronate / Generic mfg.
    Biomarker, Journal, Tumor microenvironment:  Tumor microenvironment reprogramming improves nanomedicine-based chemo-immunotherapy in sarcomas. (Pubmed Central) -  Jun 28, 2024   
    In conclusion, H2O2?responsive DA?B?DEX presents a promising delivery system for hydrophobic anti?tumor drugs for OS therapy. Collectively, our findings provide evidence that ketotifen-induced TME reprograming can improve the efficacy of nanomedicine-based chemoimmunotherapy in sarcomas.
  • ||||||||||  elesclomol (STA-4783) / Madrigal Pharma
    Journal, Immunogenic cell death:  Copper(II)-Based Nano-Regulator Correlates Cuproptosis Burst and Sequential Immunogenic Cell Death for Synergistic Cancer Immunotherapy. (Pubmed Central) -  Jun 28, 2024   
    To trigger cuproptosis, copper-ionophore elesclomol (ES) had to be employed for the copper-transporting-mediated process...This enabled an increased infiltration of cytotoxic CD8+ T cells and consequently enhanced antitumor immune responses for successfully suppressing fibrosarcoma growth. Thus, the copper(II)-based metal-organic framework nano-regulator offered a promising approach for inducing cuproptosis and cuproptosis-stimulated ICD for cancer immunotherapy.
  • ||||||||||  Journal:  Thrombospondin 4, a mediator and candidate indicator of pain. (Pubmed Central) -  Jun 27, 2024   
    This effect is mediated by regulation of neuron excitability via inhibition of synapsin I (Syn I) and modulation of excitatory and inhibitory presynaptic transmission via regulation of vesicular glutamate transporter 2(Vglut2), vesicular GABA transporter (VGAT), and glutamate decarboxylase (GAD) expression. The present study provides a replicable, predictive, valid indicator of pain and demonstrated the underlying molecular and electrophysiological mechanisms by which TSP4 contributes to pain.
  • ||||||||||  Journal:  Spindle cell sarcoma of the chest wall: a pediatric case report. (Pubmed Central) -  Jun 27, 2024   
    The patient was successfully treated with surgery and adjuvant chemoradiotherapy. We hope to add to our academic knowledge by presenting the presentation and treatment of SCS in a pediatric patient.
  • ||||||||||  Review, Journal:  Nasal Cavity and Paranasal Sinus Cancer: Diagnosis and Treatment. (Pubmed Central) -  Jun 27, 2024   
    The other 2990 cases of total 3824 were treated with multimodality treatment. The diagnosis and treatment of sinonasal cancers require a interdisciplinary approach and multimodality treatment.
  • ||||||||||  Journal:  Innovations in the classification of soft tissue tumors (Pubmed Central) -  Jun 27, 2024   
    There were further additions to vascular soft tissue tumors, smooth muscle cell tumors, peripheral nerve sheath tumors and tumors of uncertain differentiation. A
  • ||||||||||  Journal:  Auranofin and reactive oxygen species inhibit protein synthesis and regulate the level of the PLK1 protein in Ewing sarcoma cells. (Pubmed Central) -  Jun 27, 2024   
    In particular, we identified that both hydrogen peroxide and auranofin, an inhibitor of thioredoxin reductase and regulator of oxidative stress and reactive oxygen species, activate the repressor of protein translation 4E-BP1 and reduce the levels of the oncogenic proteins RRM2 and PLK1 in Ewing and other sarcoma cell lines. These results provide novel insight into the mechanism of how ROS-inducing drugs target cancer cells via inhibition of protein translation and identify a mechanistic link between ROS and the DNA replication (RRM2) and cell cycle regulatory (PLK1) pathways.
  • ||||||||||  doxorubicin hydrochloride / Generic mfg.
    Journal:  A case report of primary pericardial sarcoma. (Pubmed Central) -  Jun 27, 2024   
    Transthoracic echocardiogram and computed tomography are often the initial tests of choice for pericardial effusions with pericardiocentesis recommended for effusions with tamponade physiology, for moderate-to-large effusions, or if there is concern for infection/neoplasm. Due to improved tissue characterization and spatial resolution, CMR and positron emission tomography should also be considered for atypical or recurrent pericardial effusions to assess for less common aetiologies such as malignancy.
  • ||||||||||  cisplatin / Generic mfg.
    Journal:  FoxG1/BNIP3 axis promotes mitophagy and blunts cisplatin resistance in osteosarcoma. (Pubmed Central) -  Jun 27, 2024   
    Frequency of complications is similar in elderly patients compares to younger patients group. FoxG1 overexpression promoted BNIP3 expression, enhanced mitophagy in CDDP-resistant OS cells, and resensitized the resistant cells to CDDP treatment in
  • ||||||||||  Journal:  Enhancing radiographic image interpretation: WARES-PRS model for knee bone tumour detection. (Pubmed Central) -  Jun 27, 2024   
    The detection and classification efficiency is validated with various measures and the experimental results revealed that the detection accuracy is enhanced for the proposed approach by 98.5%. The outcomes of our study have exhibited a substantial contribution to assisting physicians in the detection of knee bone tumours.
  • ||||||||||  methotrexate / Generic mfg.
    Journal:  Antitumoral-Embedded Biopolymeric Spheres for Implantable Devices. (Pubmed Central) -  Jun 27, 2024   
    Bio-simulated tests performed for up to one week evidenced the gradual release of the antitumor drug and the biomineralization potential of PLGA/HA-MTX sphere coatings. The composite materials proved superior biocompatibility and promoted enhanced cell adhesion and proliferation with respect to human preosteoblast and osteosarcoma cell lines when compared to pristine titanium.
  • ||||||||||  Review, Journal, Heterogeneity:  Amicis Omnia Sunt Communia: NF-?B Inhibition as an Alternative to Overcome Osteosarcoma Heterogeneity. (Pubmed Central) -  Jun 27, 2024   
    In silico strategies were used to demonstrate that NF-?B is closely coordinated with other commonly dysregulated signaling pathways not only by functionally interacting with several of their members but also by actively participating in the regulation of their transcription. While existing inhibitors lack selectivity or act indirectly, the therapeutic potential of targeting NF-?B is indisputable, first for its multifunctionality on most cancer hallmarks, and secondly, because, as a common downstream effector of the many dysregulated pathways influencing OS aggressiveness, it turns complex regulatory networks into a simpler picture underneath molecular heterogeneity.
  • ||||||||||  Biomarker, Journal, PD(L)-1 Biomarker, IO biomarker:  Prognostic Role of OX40, LAG-3, TIM-3 and PD-L1 Expression in Bone and Soft Tissue Sarcomas. (Pubmed Central) -  Jun 27, 2024   
    There was no significant relationship between the PDL-1 staining percentage of tumor cells and OX40, TIM-3, and LAG-3 staining in inflammatory cells with the OS of sarcoma patients. However, detecting a significant positive correlation between PDL-1 staining and TIM-3 and LAG-3 staining also holds promise for finding effective targetable combination therapies that can prolong survival in sarcoma patients in the future.